Clinical Trial Update: Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial investigating donor regulatory T-cells for chronic graft-versus-host disease in patients who do not achieve complete remission with rux…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Donor regulatory T-cells
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Conditions: Chronic Graft vs Host Disease | Phase 2 | Status: UNKNOWN